Visual and Anatomic Outcomes following Cataract Surgery in Patients with Pre-operative Macular Edema Due to Retinal Vein Occlusions Managed with Intravitreal anti-VEGF.


Journal

Seminars in ophthalmology
ISSN: 1744-5205
Titre abrégé: Semin Ophthalmol
Pays: England
ID NLM: 8610759

Informations de publication

Date de publication:
18 May 2020
Historique:
pubmed: 30 7 2020
medline: 2 7 2021
entrez: 30 7 2020
Statut: ppublish

Résumé

The purpose of this study was to investigate the visual and anatomic outcomes in patients with macular edema due to retinal vein occlusions (RVO) who were actively managed with intravitreal anti-vascular endothelial growth factor (VEGF) before and after cataract surgery. Retrospective, cohort study of all patients with RVO who underwent cataract surgery and were receiving intravitreal anti-VEGF injections from January 1st, 2012 through October 31st, 2018. There were 31 eyes that underwent cataract surgery and received at least one intravitreal anti-VEGF injection for a diagnosis of RVO within 6 months prior to surgery. Data collected included the development of subretinal or intraretinal macular fluid in the 6 months following surgery, timing of injections, number of injections, best corrected visual acuity (BCVA), and central subfield thickness (CST). There was a significant improvement between pre- and post-operative BCVA when comparing all eyes ( Patients with cataracts who are actively managed for macular edema due to RVO with anti-VEGF agents may undergo cataract surgery, knowing they will have a transient increase in macular thickness that resolves without adjusting the frequency of intravitreal injections and is not visually significant.

Identifiants

pubmed: 32721186
doi: 10.1080/08820538.2020.1772319
doi:

Substances chimiques

Angiogenesis Inhibitors 0
Glucocorticoids 0
Vascular Endothelial Growth Factor A 0
Bevacizumab 2S9ZZM9Q9V
Dexamethasone 7S5I7G3JQL
Ranibizumab ZL1R02VT79

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

205-209

Auteurs

Matthew R Starr (MR)

Department of Ophthalmology, Mayo Clinic , Rochester, Minnesota, USA.

Michael A Mahr (MA)

Department of Ophthalmology, Mayo Clinic , Rochester, Minnesota, USA.

Raymond Iezzi (R)

Department of Ophthalmology, Mayo Clinic , Rochester, Minnesota, USA.

Andrew J Barkmeier (AJ)

Department of Ophthalmology, Mayo Clinic , Rochester, Minnesota, USA.

Sophie J Bakri (SJ)

Department of Ophthalmology, Mayo Clinic , Rochester, Minnesota, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH